Summary:
A randomized, double-blind, parallel-group, multicenter study of secukinumab to commpare 300 mg and 150 mg at week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achiving inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150 mg ( ASLeap )
Qualified Participants May Receive:
Free treatment, Doctor visits, Laboratory results, Compensation of $40.00 per visit completed if patient qualifies.